Dosage Instructions for Maximum Benefit & Relief

TheraLife Eye Autoimmune

For people with autoimmune diseases such as Sjogren’s, Rheumatoid Arthritis, Ocular Rosacea, Graves’ Disease, Raynaud’s, Lupus, Bone Marrow Transplantation, Graft Versus Host, and more.

Additional Dosage Notes

Theralife® recommends an initial dosage of 8 capsules per day for the first week of treatment, followed by successive decreases in dosage levels as treatment continues (see Dosage Instructions above). This regimen works well for most people with mild to moderate dry eyes who are generally in good health. For those with severe dry eyes, the initial dosage of 8 capsules per day may have to be extended beyond the first week, especially for patients with auto-immune diseases such as Sjorgren’s Syndrome.

A question that often arises is: How many capsules should be taken once dry eye symptoms are alleviated or normal tear secretion is established? The appropriate maintenance dosage for you will depend on many physiological and environmental factors such as: age, medical conditions and medications, exercise level, weather, hormonal balance, and others.

Dry eye conditions may flare up or become more severe from time to time, due to the factors discussed earlier. To help with the discomfort caused by these flare ups, Theralife® recommends taking additional capsules prior to and during travel on airplanes, active outdoor sports activities, sudden humidity changes (especially due to altitude changes), and other seasonal changes. Wearing wrap-around sun glasses is also highly recommend for outdoor activities to protect your eyes from sun and wind.

In short, you can always take additional capsules of Theralife® Eye Enhanced when dry eye symptoms flare up or when you know that you will be encountering conditions which may aggravate your dry eye symptoms.

REFERENCES

• AARDA (American Autoimmune Related Diseases Association). AARDA survey study. Eastpointe, MI: American Autoimmune Related Diseases Association; 2017. [July 8, 2021]. https://www​.aarda.org​/wp-content/uploads​/5yr-Survey-Study-REPORT-updated-2017​.pdf .
• Abbas AK, Lohr J, Knoechel B, Nagabhushanam V. T cell tolerance and autoimmunity. Autoimmunity Reviews. 2004;3(7-8):471–475. https://doi​.org/10.1016/j​.autrev.2004.07.004 . [PubMed]
• Abramson O, Durant M, Mow W, Finley A, Kodali P, Wong A, Tavares V, McCroskey E, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Perry GS, Cannon R, Herrinton LJ. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in northern California, 1996 to 2006. Journal of Pediatrics. 2010;157(2):233–239. e231. https://doi​.org/10.1016/j​.jpeds.2010.02.024 . [PubMed]
• Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: A systematic review of the literature. Journal of Medical Economics. 2013;16(5):639–647. https://doi​.org/10.3111/13696998​.2013.778268 . [PubMed]
• Aggarwal R, Anaya J-M, Koelsch KA, Kurien BT, Scofield RH. Association between secondary and primary Sjögren’s syndrome in a large collection of lupus families. Autoimmune Diseases. 2015a;2015:298506. https://doi​.org/10.1155/2015/298506 . [PMC free article] [PubMed]
• Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, Brunner HI, Ogawa R, Felson D, Ogdie A, Aletaha D, Feldman BM. Distinctions between diagnostic and classification criteria? Arthritis Care & Research. 2015b;67(7):891–897. https://doi​.org/10.1002/acr.22583 . [PMC free article] [PubMed]
• Albuquerque BC, Salles VB, Tajra RDdP, Rodrigues CEM. Outcome and prognosis of patients with lupus nephritis submitted to renal transplantation. Scientific Reports. 2019;9(1):11611. https://doi​.org/10.1038​/s41598-019-48070-y . [PMC free article] [PubMed]
• American Board of Medical Specialties. Specialty and subspecialty certificates. [January 26, 2022]. n.d. https://www​.abms.org​/member-boards/specialty-subspecialty-certificates .
• American College of Rheumatology. Criteria. [January 26, 2022]. https://www​.rheumatology​.org/PracticeQuality​/Clinical-Support/Criteria .
• Anaya JM. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmunity Reviews. 2012;11(11):781–784. https://doi​.org/10.1016/j​.autrev.2012.02.002 . [PubMed]
• Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, Berndt SI, Ricker W, Parsons R, Engels EA. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. International Journal of Cancer. 2009;125(2):398–405. https://doi​.org/10.1002/ijc.24287 . [PMC free article] [PubMed]
• Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, Herrinton LJ. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiology and Drug Safety. 2013;22(8):842–849. https://doi​.org/10.1002/pds.3447 . [PMC free article] [PubMed]
• Autoimmune Association. Autoimmune disease list. 2021. [November 29, 2021]. https://autoimmune​.org/about-us .
• Autoimmune Registry Inc. The autoimmune diseases. 2020. [April 12, 2021]. https://www​.autoimmuneregistry​.org/autoimmune-diseases .
• Autoimmune Registry, Inc. About Autoimmune Registry, Inc. 2021. [June 22, 2021]. https://www​.autoimmuneregistry​.org/about-us .
• Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World Journal of Gastroenterology. 2016;22(20):4794–4801. https://doi​.org/10.3748/wjg.v22.i20.4794 . [PMC free article] [PubMed]
• Baer AN, Maynard JW, Shaikh F, Magder LS, Petri M. Secondary Sjögren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. Journal of Rheumatology. 2010;37(6):1143–1149. https://doi​.org/10.3899/jrheum.090804 . [PubMed]
• Bailey ZD, Feldman JM, Bassett MT. How structural racism works – racist policies as a root cause of U.S. racial health inequities. New England Journal of Medicine. 2021;384(8):768–773. https://doi​.org/10.1056/NEJMms2025396 . [PubMed]
• Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, Grassi S, Alpigiani MG, Barbano G, Janz-Junior LL, Martini A, Ravelli A. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus. 2006;15(8):515–520. https://doi​.org/10.1191​/0961203306lu2316oa . [PubMed]
• Barnabe C, Joseph L, Belisle P, Labrecque J, Edworthy S, Barr SG, Fritzler M, Svenson LW, Hemmelgarn B, Bernatsky S. Prevalence of systemic lupus erythematosus and systemic sclerosis in the first nations population of Alberta, Canada. Arthritis Care & Research. 2012;64(1):138–143. https://doi​.org/10.1002/acr.20656 . [PubMed]
• Barnado A, Casey C, Carroll RJ, Wheless L, Denny JC, Crofford LJ. Developing electronic health record algorithms that accurately identify patients with systemic lupus erythematosus. Arthritis Care & Research. 2017;69(5):687–693. https://doi​.org/10.1002/acr.22989 . [PMC free article] [PubMed]
• Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Margaretten M, Chernitskiy V, Graf J, Imboden J, Yelin E. Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics. Arthritis Care & Research. 2011;63(9):1238–1246. https://doi​.org/10.1002/acr.20525 . [PMC free article] [PubMed]
• Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. [PMC free article] [PubMed]
• Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell’Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC. Somatic mutations in uba1 and severe adult-onset autoinflammatory disease. New England Journal of Medicine. 2020;383(27):2628–2638. https://doi​.org/10.1056/NEJMoa2026834 . [PMC free article] [PubMed]
• Beko E, Pervaiz S, Nanda V, Dhawan S. Long-term follow-up of patients with diffuse fasciitis and eosinophilia associated with l-tryptophan ingestion. Cutis. 1993;51(4):266–270. [PubMed]
• Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: Conceptual models, empirical challenges and interdisciplinary perspectives. International Journal of Epidemiology. 2002;31(2):285–293. https://doi​.org/10.1093/ije/31.2.285 . [PubMed]
• Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: A meta-analysis. Inflammatory Bowel Diseases. 2013;19(3):599–613. https://doi​.org/10.1097/MIB​.0b013e31827f27ae . [PMC free article] [PubMed]